Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
January 4, 2022
- Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal™
- Sibnayal™ will be marketed to one-third of European patients by three members of the exclusive ‘Your Pharma Partner’ network
Paris, France, 4 January 2022 – 7:00am (CET) – Advicenne (Euronext: ADVIC) (or the “Company”), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that it has signed an exclusive distribution agreement with FrostPharma AB (“FrostPharma”), a Swedish pharmaceutical company, for the commercialization of Sibnayal™ in the Nordic region (Denmark, Finland, Iceland, Norway, and Sweden).